Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lille – page 57

1 329 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lille at a glance
1 329
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 329 trials in Lille

Open in trial search

Henoch-Schonlein purpura

Not yet recruiting

Study of rituximab and glucocorticoids versus placebo and glucocorticoids in adults with newly diagnosed or relapsing IgA vasculitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Hospital Foch

Erythema multiforme

Not yet recruiting

Study on Severe Erythema Multiforme: Comparing Methylprednisolone Acetate and Lidocaine Hydrochloride Monohydrate with Placebo for Hospitalized Patients

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Assistance Publique Hopitaux De Paris

Stomatitis

Not yet recruiting

Study on Apremilast for Patients with Severe Recurrent Mouth Ulcers Resistant to Colchicine

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Centre Hospitalier Universitaire Rouen

Abortion threatened

Not yet recruiting

Study on Antibiotic Combination of Ceftriaxone, Clarithromycin, and Metronidazole for Pregnant Women with Threatened Miscarriage and Intact Membranes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ceftriaxone Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Neoplasm

Not yet recruiting

Study of Spartalizumab and Pazopanib for Patients with Refractory or Recurrent Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pazopanib
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Smoking cessation therapy

Not yet recruiting

Study on Using Nicotine Electronic Cigarettes and Varenicline for Smoking Cessation in Smokers of 10+ Cigarettes Daily

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Varenicline
  • Sponsor:Assistance Publique Hopitaux De Paris

Prostate cancer+1

Not yet recruiting

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:ARTIC

Plasma cell myeloma

Not yet recruiting

Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Ductal adenocarcinoma of pancreas

Not yet recruiting

Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Association Gercor

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

  • Advanced cancer therapies
  • Targeted molecular treatments
  • Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

  • Neurodegenerative diseases
  • Movement disorders
  • Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

  • Inflammatory bowel diseases
  • Immunotherapy approaches
  • Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.